Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Opdualag 240 mg/80 mg concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
nivolumab , relatlimab
Company:  
Bristol Myers Squibb Pharmaceuticals limited See contact details
ATC code: 
L01FY02
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs Live Chat HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

UK Opdualag (nivolumab and relatlimab) Patient Card

This card is part of the marketing authorisation for Opdualag (nivolumab and relatlimab) and contains important safety information that you need to be aware of. Please also ensure that you carry this card with you at all times to inform any healthcare professional treating you (e.g., emergency department personnel) that you are receiving treatment with nivolumab and relatlimab.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Bristol Myers Squibb Pharmaceuticals limited
Company image
Address
Bristol-Myers Squibb, ARC Uxbridge, Sanderson Road, New Denham, Denham, Buckinghamshire, UB8 1DH, UK
Telephone
+44 (0)1895 523 000
Medical Information e-mail
[email protected]
Medical Information Direct Line
+44 (0) 800 731 1736
Medical Information Website
https://www.bmsmedinfo.co.uk/